Among those consuming UPFs in high-income countries, intake varies significantly across age and socioeconomic status.

The London Cancer Hub has been identified as a key district for ‘frontier innovation’ by London Mayor Sadiq Khan.

Neurocrine has commenced a Phase III registrational programme to assess NBI-1117568 as a treatment for schizophrenia in adult ...

Amylyx has dosed the first subject in the Phase III LUCIDITY trial of avexitide for treating post-bariatric hypoglycaemia ...

In a dynamic environment, an expert shares insights into potential AI applications in the clinical research setting at OCT ...